Pharmos Report issue

For profit Phase 2 Phase 3
Founded: Iselin NJ United States (1982)
Status: No NME R&D (1982)

Organization Overview

First Clinical Trial
2001
NCT00129857
First Marketed Drug
1998
loteprednol (lotemax)
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

PHARMOS | President and CFO, Pharmos

Active Ingredients

Marketed Drugs (1)

loteprednol (lotemax) (1998)

Drugs in Phase 3 Trials (1)

cannabidiol (Epidiolex) (1 trial)

Drugs in Phase 2 Trials (3)

dextofisopam (1 trial)

diclofenac (voltaren) (1 trial)

levotofisopam (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Gout (Phase 2)

Hyperuricemia (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Syndrome (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4